Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fisher Scientific

This article was originally published in The Gray Sheet

Executive Summary

Life-sciences and biochemicals segments are bolstered through acquisition of Oxoid Group Holdings for $330 mil. and Dharmacon for $80 mil. under separate definitive agreements. Oxoid adds $155 mil. in revenue from microbiological culture media and other products to test for bacterial contamination, used in research labs, drug production and process validation. Dharmacon, with sales of $17 mil., provides RNA-based products for life science research and drug discovery. "We anticipate sales of higher-margin, proprietary products to increase from 45% to approximately 50% of total sales as a result of these acquisitions," Fisher says...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT019793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel